Aurinia Pharmaceuticals Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Peter Greenleaf
Chief executive officer
US$8.8m
Total compensation
| CEO salary percentage | 9.0% |
| CEO tenure | 5yrs |
| CEO ownership | 0.2% |
| Management average tenure | 3.8yrs |
| Board average tenure | 4.4yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$78m |
| Sep 30 2023 | n/a | n/a | -US$77m |
| Jun 30 2023 | n/a | n/a | -US$73m |
| Mar 31 2023 | n/a | n/a | -US$97m |
| Dec 31 2022 | US$9m | US$791k | -US$108m |
| Sep 30 2022 | n/a | n/a | -US$115m |
| Jun 30 2022 | n/a | n/a | -US$157m |
| Mar 31 2022 | n/a | n/a | -US$168m |
| Dec 31 2021 | US$1m | US$724k | -US$181m |
| Sep 30 2021 | n/a | n/a | -US$156m |
| Jun 30 2021 | n/a | n/a | -US$148m |
| Mar 31 2021 | n/a | n/a | -US$127m |
| Dec 31 2020 | US$11m | US$673k | -US$103m |
| Sep 30 2020 | n/a | n/a | -US$129m |
| Jun 30 2020 | n/a | n/a | -US$110m |
| Mar 31 2020 | n/a | n/a | -US$102m |
| Dec 31 2019 | US$5m | US$438k | -US$88m |
Compensation vs Market: Peter's total compensation ($USD8.84M) is above average for companies of similar size in the German market ($USD1.29M).
Compensation vs Earnings: Peter's compensation has increased whilst the company is unprofitable.
CEO
Peter Greenleaf (53 yo)
5yrs
Tenure
US$8,837,397
Compensation
Mr. Peter S. Greenleaf, M.B.A., is Director at NVN Liquidation Inc. He serves as Director at ValenzaBio, Inc. since August 2022. He has been President, Chief Executive Officer and Director of Aurinia Pharm...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5yrs | US$8.84m | 0.22% $ 1.4m | |
| Chief Financial Officer | 4yrs | US$3.29m | 0.078% $ 513.5k | |
| Executive Vice President of Operations & Strategy | no data | US$3.31m | 0.11% $ 695.9k | |
| Executive VP | 3.4yrs | US$3.24m | 0.054% $ 358.8k | |
| Executive Vice President of Research & Development | 1.8yrs | US$3.24m | no data | |
| Head of the Corporate Communications & Investor Relations | no data | no data | no data | |
| Vice President of Sales | 4.2yrs | no data | no data | |
| Chief Business Officer | 3.8yrs | US$702.00k | 0% $ 0 | |
| Senior Vice President of Global Regulatory Affairs | no data | no data | no data | |
| Chief Commercial Officer | 1.8yrs | no data | 0.051% $ 338.6k | |
| Vice President of Investor Relation | no data | no data | no data |
3.8yrs
Average Tenure
53yo
Average Age
Experienced Management: IKAP's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5yrs | US$8.84m | 0.22% $ 1.4m | |
| Director | less than a year | US$1.10m | no data | |
| Independent Director | 4.8yrs | US$262.37k | 0.010% $ 68.3k | |
| Independent Director | 4.4yrs | US$264.87k | 0.0064% $ 42.2k | |
| Director | less than a year | no data | no data | |
| Chairman | 5yrs | US$244.87k | 0.023% $ 152.9k | |
| Director | less than a year | no data | no data | |
| Independent Non-Executive Director | 8.9yrs | US$262.37k | 0.028% $ 183.2k | |
| Independent Director | 2.8yrs | US$256.49k | 0.012% $ 82.7k |
4.4yrs
Average Tenure
65yo
Average Age
Experienced Board: IKAP's board of directors are considered experienced (4.4 years average tenure).